methylprednisolone has been researched along with Genetic Diseases in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (50.00) | 29.6817 |
2010's | 1 (50.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Abdel-Azim, H; Crooks, GM; Kapoor, N; Khazal, S; Kohn, DB; Mahadeo, KM; Shah, AJ; Zhao, Q | 1 |
Akpek, G; Anders, V; Lee, SM; Vogelsang, GB | 1 |
2 other study(ies) available for methylprednisolone and Genetic Diseases
Article | Year |
---|---|
Unrelated donor hematopoietic stem cell transplantation for the treatment of non-malignant genetic diseases: An alemtuzumab based regimen is associated with cure of clinical disease; earlier clearance of alemtuzumab may be associated with graft rejection.
Topics: Adolescent; Alemtuzumab; Antibodies, Monoclonal, Humanized; Busulfan; Child; Child, Preschool; Cyclophosphamide; Cyclosporine; Drug Administration Schedule; Female; Gene Expression; Genetic Diseases, Inborn; Graft Rejection; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; HLA Antigens; Humans; Immunosuppressive Agents; Infant; Male; Methylprednisolone; Myeloablative Agonists; Pilot Projects; Survival Analysis; Tacrolimus; Transplantation Conditioning; Transplantation, Homologous; Unrelated Donors; Vidarabine | 2015 |
A high-dose pulse steroid regimen for controlling active chronic graft-versus-host disease.
Topics: Adolescent; Adult; Bone Marrow Transplantation; Child; Child, Preschool; Chronic Disease; Disease Progression; Drug Administration Schedule; Drug Evaluation; Female; Follow-Up Studies; Genetic Diseases, Inborn; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Infant; Infection Control; Life Tables; Male; Methylprednisolone; Middle Aged; Retrospective Studies; Survival Analysis; Treatment Outcome | 2001 |